U.S. Luxury Stock News

Union Pacific (UNP) is back in focus after agreeing to let Amtrak run passenger trains over a 5 mile stretch of its track near Avondale, Louisiana, starting April 1, 2026. See our latest analysis for Union Pacific. The agreement with Amtrak comes as Union Pacific’s share price, at $243.12, sits after a mixed stretch, with a 30 day share price return showing an 8.93% decline but a 90 day share price return of 5.10% and a 3 year total shareholder return of 34.11%. This suggests that longer term...

Truist Securities recently reiterated its Hold rating on Pebblebrook Hotel Trust while citing improving fundamentals such as San Francisco’s recovery, easier 2026 comparisons, one-off events, and leverage reduction through asset sales, alongside a Q4 2025 earnings per share result that exceeded expectations despite softer revenue. At the same time, Pebblebrook went ex-dividend on March 31, 2026, reinforcing investor attention on income returns even as consensus analyst views remain broadly...

Kennedy-Wilson Holdings (KW) has drawn investor attention after recent trading left the real estate investment company with a market value of about US$1.5b and a last close near US$10.83 per share. See our latest analysis for Kennedy-Wilson Holdings. Recent trading leaves the 1-year total shareholder return at 32.93%. The 90-day share price return of 12% contrasts with weaker 3-year and 5-year total shareholder returns of 18.99% and 29.93% declines, and this may hint at improving momentum...

Index changes put Molina Healthcare in focus Molina Healthcare (MOH) has been removed from the FTSE All-World Index and added to the Russell Small Cap Comp Value and Growth Indices, a reshuffle that can influence trading flows and institutional ownership. These moves often prompt index-tracking funds to adjust positions, which can affect liquidity and short term price behavior. For current and prospective shareholders, they raise practical questions about how MOH is being classified in the...

W. P. Carey (WPC) is drawing fresh attention after completing about $580 million in first quarter investments, capped by a $210 million Canadian auto dealership sale leaseback and active capital markets activity that supported these deals. See our latest analysis for W. P. Carey. At a share price of $69.39, W. P. Carey has a 1 day share price return of 2.10% and a 90 day share price return of 7.82%. Its 1 year total shareholder return of 17.06% suggests momentum has been building over a...

Event context and recent share performance Vertex (VERX) has been drawing investor attention after a period of weaker share performance, with the stock down about 16% over the past month and about 39% over the past 3 months. See our latest analysis for Vertex. Against a backdrop of weak longer term results, including a 1 year total shareholder return of about 67% in decline, the recent 7 day share price return of 3.69% at a share price of $12.09 hints that downside momentum may be easing...

In March 2026, Synopsys, Inc. announced a multi-billion-dollar private placement of common shares with participation from new investor Elliott Investment Management L.P., and earlier that month Arm revealed a collaboration with Synopsys on the Arm AGI CPU using Synopsys’ full-stack design tools and IP. This combination of fresh capital and deeper alignment with Arm’s Neoverse ecosystem highlights Synopsys’ role in enabling next-generation custom silicon and complex compute systems. Next,...

Tarsus Pharmaceuticals (TARS) has drawn fresh attention after dosing the first participant in its Phase 2 Calliope trial of TP-05, an oral candidate aimed at preventing Lyme disease by killing infected ticks. See our latest analysis for Tarsus Pharmaceuticals. The recent TP-05 progress and TP-03 milestone in China come as the share price sits at US$70.22, with a 7 day share price return of 4.9% but a 90 day share price return showing a 14.2% decline. The 1 year total shareholder return of...

If you are wondering whether Legend Biotech's share price reflects its underlying value, this article breaks down what the current market price may be implying about the company. The stock closed at US$19.05, with returns of 8.2% over the last week and 3.3% over the last month. The 1 year return stands at a 42.7% decline and the 3 year return at a 60.5% decline. Recent coverage around Legend Biotech has focused on its position in the biotech space and how investors are reassessing risk and...

Ameresco (NYSE:AMRC) has introduced a dual Co President structure alongside the appointment of a new Chief Operating Officer. The leadership changes mark a major organizational restructure aimed at supporting growth and project execution across the business. Ameresco focuses on energy efficiency, renewable energy projects, and related services, an area that depends heavily on disciplined project management and long term contracts. As the company works across government, commercial, and...

If you are wondering whether Millrose Properties at US$28.51 still offers value after its recent run, this article will help you frame that question clearly. The stock has seen a 3.1% decline over the last 7 days and an 8.0% decline over the last 30 days, while still showing a 17.4% return over the last year and a 4.4% decline year to date. Recent news flow around Millrose Properties has focused on its position within the real estate sector and how sentiment toward property related names has...

Recent performance context for Paychex stock Paychex (PAYX) has seen its share price under pressure recently, with negative returns over the past week, month and past 3 months, and a 39.26% decline over the past year. See our latest analysis for Paychex. At a share price of US$90.91, the stock’s recent slide is consistent with its 18.96% 3 month share price decline and 39.26% 1 year total shareholder return decline. This suggests momentum has been fading as investors reassess growth prospects...

Q2 Holdings (QTWO) has partnered with Stablecore to give banks and credit unions access to stablecoins, tokenized deposits, and other digital asset products through its existing digital banking platform. See our latest analysis for Q2 Holdings. The Stablecore partnership comes as Q2 Holdings' short-term momentum has softened, with a 30-day share price return showing a 5.65% decline and a 90-day share price return showing a 34.31% decline. The three-year total shareholder return of 105.64%...

Badger Meter (NYSE:BMI) expanded its share repurchase authorization by $75 million, signaling a larger capital return program to shareholders. The move comes alongside an analyst upgrade and fresh insider share purchases, pointing to increased confidence from both the board and management. Management also highlighted continued growth in the SmartCover business, which is becoming a more visible contributor within the portfolio. Badger Meter, trading at $154.21, has had mixed share...

If you are wondering whether Atlassian's current share price reflects its true worth, the recent performance gives a lot to think about. The stock last closed at US$69.37, with a 4.4% gain over the past 7 days, a 6.0% decline over 30 days, and year to date and 1 year returns of 55.2% and 69.0% declines respectively, alongside a 55.8% decline over 3 years and a 68.1% decline over 5 years. These swings have put valuation in sharper focus for many investors, especially those comparing today's...

KORE Group Holdings (KORE) reported Q3 FY 2025 revenue of US$68.7 million with a basic EPS loss of US$0.64, alongside trailing twelve month revenue of US$285.4 million and a TTM EPS loss of US$3.57, underscoring that the business is still operating in loss-making territory. Over recent quarters the company has seen revenue hold in a fairly tight band around the US$68 million to US$73 million range, while quarterly EPS losses have moved between roughly US$0.64 and US$1.31. The focus for...

Silver is sitting at the crossroads of several powerful forces. Demand tied to AI infrastructure, solar panels and electric vehicles is colliding with years of muted mine investment and flat output, all while energy costs and supply chain risks stay in focus due to ongoing global tensions. For investors looking for clear, focused exposure to this setup, a curated screener of top silver stocks can be a helpful filter that highlights miners with stronger balance sheets and lower production...

Wondering if Fulton Financial, at a last close of US$20.58, is offering you real value right now or if the recent run has already priced in the opportunity. The stock shows a 2.4% return over the last 7 days, a 1.5% decline over 30 days, a 5.7% return year to date, and a 19.3% return over 1 year, with longer term returns of 73.6% over 3 years and 48.7% over 5 years that may hint at changing expectations around risk and reward. Recent coverage of Fulton Financial has focused on its position...

In late March 2026, Topgolf Callaway Brands (Callaway Golf) gained attention after broader market optimism followed signs of easing geopolitical tensions in Iran and reassuring Federal Reserve comments about stable interest rates. The reaction highlighted how sensitive leisure and consumer discretionary names like Callaway Golf can be to shifts in macro sentiment and interest-rate expectations, even without company-specific announcements. With the backdrop of calmer rate expectations, we’ll...

Conagra Brands (CAG) has followed up its latest quarter with mixed top and bottom line figures, reporting Q2 2026 revenue of US$2.98b and a basic EPS loss of US$1.39, alongside trailing 12 month revenue of US$11.23b and basic EPS of US$0.20. Over the past few reported quarters, revenue has moved from US$3.20b in Q2 2025 to US$2.84b in Q3 2025, US$2.78b in Q4 2025 and US$2.63b in Q1 2026, while basic EPS has shifted from US$0.60 to US$0.30, US$0.54 and US$0.34 respectively. This leaves...

Vertex Pharmaceuticals received FDA approval to expand the use of ALYFTREK and TRIKAFTA to additional age groups and CFTR gene variants. The expanded labels make CFTR modulator treatment options available to an estimated 95% of people with cystic fibrosis in the US. These decisions materially increase the eligible US patient pool for Vertex's cystic fibrosis franchise. For investors tracking NasdaqGS:VRTX, the fresh label expansions arrive as the stock trades around $447.26. Shares have...

Recently, Everus Construction Group reported earnings and revenue that exceeded analyst forecasts, alongside a record backlog in its specialized infrastructure and commercial construction services. This combination of stronger-than-expected operating results, a growing project pipeline, and increased institutional interest has sharpened investor focus on Everus’ role in data center, transmission, and distribution build-outs. With Everus’ record backlog underscoring robust demand, we’ll now...

MSC Industrial Direct (MSM) has put fresh numbers on the board for Q2 2026, with Q1 2026 revenue at US$965.7 million and basic EPS of US$0.93, set against a trailing twelve month EPS of US$3.67 on revenue of US$3.8 billion. Over recent quarters, revenue has ranged from US$891.7 million to US$978.2 million, while quarterly basic EPS has moved between US$0.70 and just over US$1.02. This gives investors a clear view of how earnings and sales have been tracking as margins come under pressure. See...

Taylor Devices (TAYD) just turned in its Q3 2026 scorecard, with recent quarterly figures showing revenue between about US$8.5 million and US$15.6 million over the past six reported quarters and EPS ranging from US$0.34 to US$1.17. Across that stretch, revenue moved from US$8.55 million in Q2 2025 to US$11.60 million in Q2 2026, while EPS shifted from US$0.34 to US$0.64, setting up a results season in which investors are paying close attention to how firmly margins are holding. See our full...